Yang Lei, Wang Hui-Hui, Wei Fu-Sheng, Ma Long-Xian
Department of Gynecology and Obstetrics, The First Affiliated Hospital of Nanchang University, Nanchang Department of Anesthesiology, Xinyu People's Hospital, Xinyu Department of Anesthesiology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P.R. China.
Medicine (Baltimore). 2017 Sep;96(38):e8093. doi: 10.1097/MD.0000000000008093.
The aim of this study was to evaluate the safety of acute normovolemic hemodilution (ANH) for patients undergoing intracranial meningioma resection.Eighty patients (aged 48-65 years) with American Society of Anesthesiologists physical status I-II undergoing intracranial meningioma resection were included in this prospective observational study. The patients were randomly divided into group A (ANH group), which underwent a combination of ANH and intraoperative cell salvage (ICS), and group B (control group), which underwent ICS alone. The study parameters were recorded as baseline values before blood drainage (T0), after blood drainage (T1), and before (T2) and after (T3) retransfusion in group A. Whereas in group B, the same parameters were measured 10 minutes after anesthesia induction (T0), before surgery (T1), and before (T2) and after (T3) transfusion of autologous blood.When intraoperative blood loss was <2000 mL, the mean volume of homologous blood transfused in group A patients was 100.8 ± 82.3 mL, compared with the 190.0 ± 91.8 mL in group B. Reduction in homologous blood used in group A was statistically significant (P < .05). In group B, 15.1% patients received homologous blood, whereas only 5.9% patients received homologous blood in group A. The difference in heart rate between both groups at different time points was statistically nonsignificant (P > .05). The mean hemoglobin and hematocrit levels at T1 and T2 in group A were lower than in group B (P < .05). The prothrombin time and activated partial thromboplastin time in both groups were prolonged significantly after T2 (all P < .05), but were all within normal range. There were no significant differences in postoperative hospital stay, mortality, and postoperative infection between the 2 groups.For patients undergoing excision of intracranial meningioma, ANH is an effective procedure to reduce the need for allogeneic transfusions.
本研究旨在评估急性等容血液稀释(ANH)用于颅内脑膜瘤切除术患者的安全性。本前瞻性观察性研究纳入了80例美国麻醉医师协会身体状况为I-II级、年龄在48 - 65岁之间且接受颅内脑膜瘤切除术的患者。患者被随机分为A组(ANH组),接受ANH与术中自体血回输(ICS)联合治疗;B组(对照组),仅接受ICS治疗。研究参数记录为A组放血前(T0)、放血后(T1)以及回输前(T2)和回输后(T3)的基线值。而在B组,相同参数于麻醉诱导后10分钟(T0)、手术前(T1)以及自体血输注前(T2)和输注后(T3)进行测量。当术中失血量<2000 mL时,A组患者输注异体血的平均量为100.8±82.3 mL,而B组为190.0±91.8 mL。A组异体血使用量的减少具有统计学意义(P<0.05)。在B组,15.1%的患者接受了异体血,而A组仅5.9%的患者接受了异体血。两组在不同时间点的心率差异无统计学意义(P>0.05)。A组T1和T2时的平均血红蛋白和血细胞比容水平低于B组(P<0.05)。两组的凝血酶原时间和活化部分凝血活酶时间在T2后均显著延长(均P<0.05),但均在正常范围内。两组术后住院时间、死亡率和术后感染方面无显著差异。对于接受颅内脑膜瘤切除术的患者,ANH是一种减少异体输血需求的有效方法。